

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**SCHEDULE 13G**

Under the Securities Exchange Act of 1934  
(Amendment No.   1  )\*

---

**Theravance Biopharma, Inc.**  
(Name of Issuer)

Ordinary Shares, par value \$0.00001 per share  
(Title of Class of Securities)

**G8807B106**  
(CUSIP Number)

**June 4, 2020**  
(Date of Event which Requires Filing of this Statement)

---

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the *Notes*).

---

---

SCHEDULE 13G

CUSIP No. G8807B106

<b>1</b>		<b>Names of Reporting Persons</b>
		Link Fund Solutions Limited
<b>2</b>		<b>Check the appropriate box if a member of a Group (see instructions)</b>
		(a) <input type="checkbox"/> (b) <input type="checkbox"/>
<b>3</b>		<b>Sec Use Only</b>
<b>4</b>		<b>Citizenship or Place of Organization</b>
		United Kingdom
<b>Number of Shares Beneficially Owned by Each Reporting Person With:</b>	<b>5</b>	<b>Sole Voting Power</b>
		0
	<b>6</b>	<b>Shared Voting Power</b>
		0
	<b>7</b>	<b>Sole Dispositive Power</b>
		0
	<b>8</b>	<b>Shared Dispositive Power</b>
		0
<b>9</b>	<b>Aggregate Amount Beneficially Owned by Each Reporting Person</b>	
	0	
<b>10</b>	<b>Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)</b>	
	<input type="checkbox"/>	
<b>11</b>	<b>Percent of class represented by amount in row (9)</b>	
	0%	
<b>12</b>	<b>Type of Reporting Person (See Instructions)</b>	
	CO	

**Item 1.**

(a) **Name of Issuer:** Theravance Biopharma, Inc. (the "Issuer")

(b) **Address of Issuer's Principal Executive Offices:**

PO Box 309  
Ugland House, South Church Street,  
George Town, Grand Cayman KY1-1104, Cayman Islands

**Item 2.**

(a) **Name of Person Filing:** Link Fund Solutions Limited ("LFS")

(b) **Address of Principal Business Office or, if None, Residence:** 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom

(c) **Citizenship:** United Kingdom

(d) **Title and Class of Securities:** Ordinary Shares, par value \$0.00001 per share (the "Ordinary Shares")

(e) **CUSIP No.:** G8807B106

**Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

- (a)  Broker or dealer registered under Section 15 of the Act;
- (b)  Bank as defined in Section 3(a)(6) of the Act;
- (c)  Insurance company as defined in Section 3(a)(19) of the Act;
- (d)  Investment company registered under Section 8 of the Investment Company Act of 1940;
- (e)  An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
- (f)  An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
- (g)  A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
- (h)  A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i)  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
- (j)  A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
- (k)  Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: \_\_\_\_\_

---

**Item 4. Ownership**

The information required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page and is incorporated herein by reference.

The percentage set forth in Row 11 of this Schedule 13G (Amendment No. 1) is calculated based upon 63,088,131 Ordinary Shares issued and outstanding as of April 30, 2020, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2020, filed with the Securities and Exchange Commission on May 8, 2020.

**Item 5. Ownership of Five Percent or Less of a Class.**

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following .

**Item 6. Ownership of more than Five Percent on Behalf of Another Person.** Not applicable.

**Item 7. Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.** Not applicable.

**Item 8. Identification and classification of members of the group.** Not applicable.

**Item 9. Notice of Dissolution of Group.** Not applicable.

**Item 10. Certifications.**

---

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: 23 June 2020

LINK FUND SOLUTIONS LIMITED

By: /s/ Nigel Boyling

Name: Nigel Boyling

Title: Director

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

**Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).**